Aribio Co., Ltd.
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on neurodegenerative and infectious diseases. AR1003 is the lead candidate for sepsis and COVID-19, which is preparing to enter a Phase 1 study in the United States by early 2021.
Last updated on
About Aribio Co., Ltd.
Founded
2010Employees
51-250Category
Industry
BiotechnologyLocation
City
PangyoCountry
South KoreaTech Stack (20)
